Author: Fiona Craig
-

Monro Shares Jump Nearly 9% After Beating Revenue Forecasts in Q4
Monro, Inc. (NASDAQ:MNRO) saw its stock surge 8.85% in premarket trading Wednesday after the company topped revenue expectations for its fiscal fourth quarter, even as it reported a deeper loss than anticipated. The auto service and tire company posted $295 million in revenue for the quarter ending March 29, 2025, exceeding analysts’ projection of $288.58…
-

Edwards Lifesciences Gains Ground After Rival Exits Valve Market
Edwards Lifesciences (NYSE:EW) saw its shares rise by 3% following news that competitor Boston Scientific (NYSE:BSX) is exiting the aortic valve market. Boston Scientific announced it will cease global distribution of its ACURATE neo2 and ACURATE Prime Aortic Valve Systems and abandon its efforts to secure U.S. FDA approval. The company attributed the decision to…
-

Mobileye Shares Climb After Securing Major Radar Technology Deal
Mobileye Global (NASDAQ:MBLY) saw its shares jump over 5% in premarket trading Wednesday following news of a significant contract award from a prominent global car manufacturer. The company will supply its advanced imaging radar system for the automaker’s future line of autonomous vehicles. The radar will play a central role in a hands-free, eyes-off driving…
-

What’s Moving US Markets Today: Nvidia Earnings, New Stellantis CEO, and Japanese Bond Auction
U.S. stock futures edged lower on Wednesday ahead of a highly anticipated earnings report from Nvidia, the semiconductor powerhouse that has been a key player benefiting from the surge in AI-related demand. Meanwhile, Stellantis announced a new CEO appointment, and a weak Japanese government bond auction sparked concerns about demand for long-term debt. Nvidia’s Earnings…
-

Gold Prices Slip Amid Tariff Relief and Dollar Strength, Despite Lingering Economic Uncertainty
Gold prices dipped during Asian trading on Wednesday, pressured by a growing risk appetite following U.S. President Donald Trump’s decision to delay imposing steep tariffs on the European Union. The move eased some fears of a trade escalation, encouraging investors to favor riskier assets over traditional safe havens like gold. Alongside gold, other metals faced…
-

Bitcoin Holds Steady Near $109K as Legislative Backing Emerges at 2025 Conference
Bitcoin (COIN:BTCUSD) maintained a steady position on Wednesday, hovering just below its recent all-time high as investors closely watched updates from the ongoing Bitcoin 2025 conference in Las Vegas. The world’s leading cryptocurrency was largely flat at around $109,030 as of early Wednesday morning – 01:41 ET. Last Thursday, Bitcoin hit a record peak approaching…
-

Oil Prices Edge Higher Amid Sanction Concerns and Upcoming OPEC+ Meeting
Oil prices experienced a modest rise during Wednesday’s Asian trading session as investors weighed the risks of potential new sanctions on Russia alongside slow progress in nuclear negotiations between the U.S. and Iran. These factors contributed to concerns over possible disruptions in the global oil supply. Meanwhile, market participants remained cautious ahead of a key…
-

NeuroPace Shares Plunge After Mixed Clinical Trial Results
NeuroPace Inc. (NASDAQ:NPCE) saw its stock nosedive by 36.1% today after announcing that its NAUTILUS clinical trial failed to meet its primary effectiveness target across the full patient population. The study was aimed at assessing the RNS System as a treatment for drug-resistant idiopathic generalized epilepsy (IGE). Despite the disappointing topline efficacy results, the study…
-

Eos Energy Shares Drop 10% Following Sudden CFO Departure
Shares of Eos Energy Enterprises Inc. (NASDAQ:EOSE) fell sharply by 10.1% after the abrupt termination of CFO Eric Javidi was announced on May 27, 2025. The company emphasized that Javidi’s departure was “without cause” and unrelated to any financial discrepancies or disagreements. He is expected to receive severance in line with his offer letter. Despite…
-

Eli Lilly Expands Pain Treatment Pipeline with SiteOne Therapeutics Acquisition
Eli Lilly and Company (NYSE:LLY) is advancing its neuroscience portfolio by acquiring SiteOne Therapeutics in a deal valued at up to $1 billion, reinforcing its focus on non-opioid pain therapies. The acquisition centers on SiteOne’s STC-004, a Phase 2-ready Nav1.8 inhibitor designed to provide relief for chronic pain sufferers without the risks of addiction associated…